Navigation Links
Campbell Alliance Brand Management Practice to Present at EyeForPharma's Oncology Summit USA and Oncology Market Access Europe Conference

RALEIGH, N.C., March 10 /PRNewswire/ -- Campbell Alliance, the leading management consulting firm specializing in the pharmaceutical and biotech industry, today announced that Ashwin Dandekar, Vice President, Brand Management Practice, will present a session at EyeforPharma's Oncology Summit USA on March 30 and 31, 2009 at the Boston Park Plaza Hotel in Boston, Massachusetts. Dr. Dandekar will also present a workshop at EyeForPharma's Oncology Market Access Europe Conference, scheduled for April 22 and 23, 2009 at the Zurich Marriott Hotel in Zurich, Switzerland.

Dr. Dandekar's presentation at EyeforPharma's Oncology Summit USA is scheduled for 3:30 pm March 30 as a part of "Session 3: Market Access and Early Commercialization". His presentation, titled "The Building Blocks of Successful Oncology Commercialization," will examine the four building blocks for maximizing the commercial value of new oncology products. Specifically, the presentation will focus on developing long-term vision for products in tandem with comprehensive market-entry strategies, creating winning labels and development programs, assessing and developing markets, and building the company's infrastructure and resources to put into action commercialization strategies.

At EyeforPharma's Oncology Market Access Europe Conference, Dr. Dandekar will present a workshop at 2:00 pm on April 20. His workshop, also titled "The Building Blocks of Successful Oncology Commercialization," will similarly examine the essential elements of maximizing commercial value for oncology products, but will focus on commercialization in European markets.

"The oncology market is undoubtedly complicated as products themselves are complex, market competition is fierce, and there are many strategic and organizational challenges that result from the specialized nature of the products," Dr. Dandekar said. "Consequently, oncology product commercialization can be highly complex."

Dr. Dandekar leverages his training as a physician and his consulting experience to help clients across the pharmaceutical, biotech, and healthcare industries. He has particular expertise in combining clinical knowledge with sound marketing skills to assist clients with new product strategy, market analysis, and product positioning. Prior to consulting, Dr. Dandekar worked as a research analyst at the University Hospitals of Cleveland, and as a physician and administrative director at Dandekar Hospital in Bombay, India. Dr. Dandekar received his MBA from the Weatherhead School of Management at Case Western Reserve University and an MBBS from MGM Medical School and Hospital, Bombay University.

For more information on EyeforPharma's Oncology Summit USA, please visit

For more information on EyeforPharma's Oncology Market Access Europe Conference, please visit

Executives from Campbell Alliance speak at many conferences in the US and Europe each year. For a full listing of events, please refer to the company's online conference calendar at

About the Brand Management Practice at Campbell Alliance

The Brand Management Practice at Campbell Alliance can help enhance the commercial performance of products from initial launch through product maturity. The firm's team members are experts at new product planning, commercial strategy development, brand planning, product launch, and myriad other aspects of maximizing the value of pharmaceutical assets. The team has also developed commercial strategies and programs in various geographic markets, including the US, Canada, Europe, and Latin America. Services include

  • Portfolio planning
  • New product planning
  • Launch excellence
  • Growth maximization
  • Life cycle extension
  • Capability enhancement

About Campbell Alliance

Campbell Alliance is the leading management consulting firm specializing in the pharmaceutical and biotechnology industry. The firm's clients include most of the world's top-20 pharmaceutical companies, as well as numerous emerging and midsize firms. Campbell Alliance is organized into practice areas, each specializing in a critical industry function: Brand Management, Business Development, Clinical Development, Managed Markets, Sales, and Trade and Distribution. From its locations in Raleigh, NC, Parsippany, NJ, Los Angeles, San Francisco, Chicago, Boston, Philadelphia, New York City, Atlanta, and London, the firm serves clients throughout North America, Europe, and Japan. For more information on Campbell Alliance, please visit

                          James Forte
                          Director, Public and Media Relations
                          Campbell Alliance
                          919-844-7100, extension 7195

SOURCE Campbell Alliance
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Campbell Alliance Hires Joe Dillon, Expands Business Development Practice
2. Campbell Alliance Sales Practice to Present at CBIs Leadership Summit on Evolving the Pharma Sales Model
3. Nader Naeymi-Rad Appointed Chief Operating Officer at Campbell Alliance
4. Darius Naigamwalla Appointed Senior Vice President and Head of the Brand Management Practice at Campbell Alliance
5. Pharmaceutical Institute, in Collaboration With Campbell Alliance, Releases Second Edition of Breakthrough Book on the Inner Workings of the Pharmaceutical Industry
6. Campbell Alliance Clinical Development Practice to Conduct Two Workshops at 44th DIA Annual Meeting
7. Campbell Alliance Trade and Distribution Practice to Speak at CBIs Commercial Contracts and Chargeback Management Conference
8. Campbell Alliance Sales Practice to Present Workshop at SPBT Annual Conference
9. Campbell Alliance Clinical Development Practice to Present Session on Global EDC Rollout at Clinical Trials Congress, Europe
10. Campbell Alliance Adds Doug Linton, Former Cardinal Health Executive, to Executive Advisory Group
11. Campbell Alliance Managed Markets Practice to Take a Leadership Role at the CBI Forum on Effective Product Pricing and Modeling Strategies
Post Your Comments:
(Date:11/25/2015)... Studies reveal the differences in species of ... way for more effective treatment for one of the most ... --> --> Gum disease is ... yet relatively little was understood about the bacteria associated with ... by researchers from the WALTHAM Centre for Pet Nutrition together ...
(Date:11/25/2015)... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) ... chat discussion at the Piper Jaffray 27th Annual Healthcare ... discussion is scheduled for Wednesday, December 2, at 8:00 ... replay will be available for 14 days after the ... NormartVP, Corporate Communications and Business Development , BrewLife(858) 875-8629 ...
(Date:11/24/2015)... -- Cepheid (NASDAQ: CPHD ) today announced that ... and invited investors to participate via webcast. ... 1, 2015 at 11.00 a.m. Eastern Time --> ... 1, 2015 at 11.00 a.m. Eastern Time --> ... NY      Tuesday, December 1, 2015 at 11.00 ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... IIROC on behalf of the Toronto Stock Exchange, confirms ... there are no corporate developments that would cause the ... --> --> About Aeterna Zentaris ... . --> Aeterna Zentaris is a specialty ...
Breaking Biology Technology:
(Date:11/9/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), the ... entry into the automotive market with a comprehensive and ... of consumer electronics human interface innovation. Synaptics, industry-leading touch ... the automotive industry and will be implemented in numerous ... , Japan , and ...
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
(Date:10/29/2015)... Calif. , Oct. 29, 2015  The J. ... new report titled, "DNA Synthesis and Biosecurity: Lessons Learned ... the Department of Health and Human Services guidance for ... in 2010. --> ... it also has the potential to pose unique biosecurity ...
Breaking Biology News(10 mins):